5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
6a. Side effects causing cessation of therapy – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
Positive‐pressure ventilation after institution of treatment · treatment of apnea
It is very uncertain whether doxapram changes 2a. Need for positive pressure ventilation after initiation of… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
3 findings from 1 review
Chronic lung disease · treatment of apnea
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Mortality before hospital discharge · preterm infants with or at risk for apnea of prematurity
High‐dose showed no clear difference in all‐cause mortality prior to hospital discharge compared with standard‐dose strategies (low certainty).
3 findings from 1 review
RR 0.86 [0.53, 1.38]
5 studies · 723 participants
Low
RR 0.75 [0.4, 1.4]
3 studies · 333 participants
Very low
RR 0.75 [0.25, 2.3]
1 study · 238 participants
Very low
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes major neurodevelopmental disability in children aged 3 to 5 years CA compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Length of hospital stay · preterm infants at risk for apnea
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
RR 0.72 [0.47, 1.11]
3 studies · 333 participants
Very low
RR 0.68 [0.48, 0.97]
1 study · 238 participants
Low
RR 0.75 [0.6, 0.94]
5 studies · 723 participants
Moderate
Length of hospital stay · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review